Prostate cancer (PCa) is the second most common diagnosed malignant disease in men
worldwide. Although serum PSA test dramatically improved the early diagnosis of PCa, it …

As the leading culprit in cancer incidence for American men, prostate cancer continues to
pose significant diagnostic, prognostic, and therapeutic tribulations for clinicians. The vast …

Prostate cancer (PCa) is the most common type of cancer and the second leading cause of
cancer-related death in men. Despite extensive research, the molecular mechanisms …

Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Recent
advances in the non-protein coding part of human genome analysis have discovered …

Background: The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led
to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early …

Prostate cancer is the most common cancer in men and the second leading cause of cancer-
related deaths. The most used biomarker to detect prostate cancer is Prostate Specific …

The advent of next-generation sequencing methods is fuelling the discovery of multiple non-
coding RNA transcripts with direct implication in cell biology and homeostasis. This new …

Prostate cancer is the second most common cause of cancer mortality among men in the
United States. While many prostate cancers are indolent, an important subset of patients …

Recent observations of novel long non-coding RNAs (lncRNAs) have considerably altered
our understanding of cell biology. The role of lncRNAs as tumor suppressors or oncogenes …

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The
explosion in treatment advances has been witnessed in parallel with significant progress in …